Claims for Patent: 9,962,429

Summary for Patent: 9,962,429

Title:	Method for treating rhinitis with B and C-type natriuretic peptide containing chimeric ring structures
Abstract:	The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
Inventor(s):	Endo; Kyoko (Sendai, JP)
Assignee:	IGISU Co., Ltd. (Tokyo, JP) Endo; Yori (Sendai-shi, Miyagi, JP)
Application Number:	15/160,268
Patent Claims:	1. A method of treating rhinitis in a subject in need thereof comprising administering to the subject an effective amount of a therapeutic preparation comprising a chimeric peptide of C-type natriuretic peptide (CNP) and B-type natriuretic peptide (BNP) forming a ring structure by an intermolecular disulfide bond as the active ingredient, wherein the CNP is a peptide selected from the group of consisting of CNP-22 and CNP-53, wherein the BNP is a peptide selected from the group of consisting of BNP-26, BNP-32, and BNP-45, wherein the chimeric peptide has CNP activity or BNP activities, wherein the sequence of CNP-22 is SEQ ID NO: 1 and the sequence of CNP-53 is SEQ ID NO: 22, and wherein the sequence of BNP-32 is SEQ ID NO: 2, the sequence of BNP-26 is SEQ ID NO: 23 and the sequence of BNP-45 is SEQ ID NO: 24 or SEQ ID NO: 25. 2. The method of treating rhinitis according to claim 1, wherein the concentration of the chimeric peptide of CNP and BNP is 20-200 .mu.g/g of the therapeutic preparation. 3. The method of treating rhinitis according to claim 1, wherein the concentration of the chimeric peptide of CNP and BNP is 50-200 .mu.g/g of the therapeutic preparation. 4. The method of treating rhinitis according to claim 1, wherein the concentration of the chimeric peptide of CNP and BNP is 50-100 .mu.g/g of the therapeutic preparation. 5. The method of treating rhinitis according to claim 1, wherein the rhinitis is infectious rhinitis, hypersensitive non-infectious rhinitis, irritant rhinitis, atrophic rhinitis, or specific granulomatous rhinitis. 6. The method of treating rhinitis according to claim 5, wherein the infectious rhinitis is acute rhinitis or chronic rhinitis. 7. The method of treating rhinitis according to claim 5, wherein the hypersensitive non-infectious rhinitis is combined-type rhinitis (hypersensitive nose), rhinorrhea-type rhinitis, congestive-type rhinitis, or dry-type rhinitis. 8. The method of treating rhinitis according to claim 7, wherein the combined-type rhinitis (hypersensitive nose) is allergic rhinitis. 9. The method of treating rhinitis according to claim 8, wherein the allergic rhinitis is allergic rhinitis against at least one allergen selected from the group consisting of house dust, mite, cedar, orchard grass, ragweed, and cat hair. 10. The method of treating rhinitis according to claim 5, wherein the irritant rhinitis is physical irritant-induced rhinitis, chemical irritant-induced rhinitis or radiation-induced rhinitis. 11. The method of treating rhinitis according to claim 1, wherein the rhinitis is mixed-type rhinitis, sneezing/rhinorrhea-type rhinitis, or nasal-occlusion-type rhinitis. 12. The method of treating rhinitis according to claim 1, wherein the nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation. 13. The method of treating rhinitis according to claim 1, wherein the nasal drop preparation selected from a gel preparation, a liquid preparation or a spray preparation. 14. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis in a subject suffering from atopic dermatitis. 15. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis with treatment resistance to steroids. 16. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis in a subject having a difficulty in withdrawal from steroids. 17. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis with treatment resistance to antihistamine drugs. 18. The method of treating rhinitis according to claim 1, wherein the therapeutic preparation is a nasal drop preparation. 19. The method of treating rhinitis according to claim 1, wherein the chimeric peptide consists of a sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 16, and SEQ ID NO: 18.

Details for Patent 9,962,429

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allermed Laboratories, Inc.	N/A	animal allergens, standardized cat hair	Injection	103473	03/12/1974		2029-08-27